Status:
TERMINATED
TAP Block Using Liposomal Bupivacaine for Post-cesarean Delivery Analgesia- Walking Towards Recovery
Lead Sponsor:
Yale University
Conditions:
Opioid Use
Pain, Acute
Eligibility:
FEMALE
18-45 years
Phase:
PHASE4
Brief Summary
The TAP block offers analgesia by blocking the sensory nerves of the anterior abdominal wall. The procedure is performed under ultrasound guidance, after identification of the external oblique, intern...
Detailed Description
This is a double blinded, randomized controlled trial. The study will be composed of 3 groups Group 1- Transverse abdominus plain block with liposomal bupivacaine + bupivacaine (LB) Group 2 - Transver...
Eligibility Criteria
Inclusion
- Patients between the ages of 18 and 45 presenting for cesarean delivery
- ASA-1, ASA-2, ASA-3
- No allergy to morphine
- No allergy to bupivacaine
- Patients with BMI \> 45 will be excluded
- No history of anxiety
- No recent or chronic opioid use
Exclusion
- Need for Magnesium sulfate therapy
- Neonatal admission to neonatal intensive care unit
- Need for additional surgery other than cesarean delivery +/- bilateral tubal ligation (e.g. hysterectomy, cystotomy)
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 28 2023
Estimated Enrollment :
147 Patients enrolled
Trial Details
Trial ID
NCT04393207
Start Date
February 1 2022
End Date
November 28 2023
Last Update
March 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University
New Haven, Connecticut, United States, 06510